Rationale: Long-acting β-adrenergic agonists and long-acting anticholinergic agents are
recommended for the management of patients with stable chronic obstructive pulmonary …

Background: Randomized clinical trials have shown long-acting mono bronchodilator
therapy to be efficacious in improving lung function and dyspnea, while reducing …

Background. COPD is the fourth leading cause of death in the world. In the case of
exacerbations or persistent symptoms, regular treatment with long-acting bronchodilators is …

This review summarizes the long-term clinical outcomes associated with β-agonist and
anticholinergic bronchodilator use in patients with chronic obstructive pulmonary disease …

Importance Chronic obstructive pulmonary disease (COPD) is a common and deadly
disease. Long-acting inhaled β-agonists and anticholinergics, first-line medications for …

Background: Chronic obstructive pulmonary disease (COPD), a largely preventable and
manageable respiratory condition, affects an estimated 12% to 20% of adults. Long-acting …

Background Currently, there is a lack of guidelines for the use of short-acting
bronchodilators (SABD) in people admitted to hospital for acute exacerbation of chronic …

Importance The associations between cardiovascular disease (CVD) and inhaled long-
acting β 2-agonists (LABAs) or long-acting antimuscarinic antagonists (LAMAs) in chronic …

abstract Incidence, predictors and effect of discontinuation of long-acting bronchodilators on
the risk of death or hospital admission among adults with Chronic Obstructive Pulmonary …

Background Treatment of stable chronic obstructive pulmonary disease (COPD) with long-
acting bronchodilator (LABD) medications is recommended by the 2014 Global initiative for …